Please login to the form below

Not currently logged in

CAR therapies

This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.

Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA

Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA

The site in the US will produce CAR T-cell therapies for patients with blood cancers. ... CAR T-cell therapy is unlike other cancer treatments as it is a one-time treatment.

Latest news

More from news
Approximately 1 fully matching, plus 95 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • White paper: Are we prepared for the influx of CAR-Ts?

    Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies. ... With CAR-Ts continuing to take centre stage as a paradigm shift in the treatment of cancer

  • The heavy toll of COVID-19 on cancer patients

    For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover. ... New therapies that minimize hospital visits may have to be prioritized by pharmaceuticals and MedTech companies.

  • In the precision medicine era, the line between products and services is blurred

    Instead, we carried out in-depth interviews with different types of stakeholders who had considerable experience working on early CAR-T therapies and clinical trials. ... Both of these scenarios were true in the case of the CAR-T treatment.

  • Precision paediatrics: Treating patients with CAR-T

    It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.

  • Highlights in haematologic malignancy from ASH 2018

    However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....